Effect of combined or separate administration of piracetam and choline on learning and memory in the rat

Different groups of rats received combined or separate administration of different doses of piracetam (P1:100, P2:200, and P4:400 mg/kg) and choline (C1:100 and C2:200 mg/kg). Compared to control treatment, C1 significantly improved performance in a delayed alternation (DA) task, while P1, P2, P4 or P1C1 had no effect. Moreover, rats receiving P2C1 and P4C1 were significantly inferior in acquiring DA to rats receiving the vehicle or separate administration of P1, P2 or C1. The different treatments with combined or separate administration of P and C had no effect on spontaneous locomotor activity and two-way avoidance conditioning. In a recognition-task only groups C1 and P4 were able to discriminate between familiar and new objects. The combined or separate administration of P1 and C1 on NA, DA, DOPAC, 5-HT, 5-HIAA levels, CAT activity and choline uptake were measured in frontal cortex and hippocampus: the only significant effect was a 5-HT increase in the hippocampus of rats treated with C1.     

HPLC法测定吡拉西坦注射液的含量

目的:建立用高效液相色谱测定吡拉西坦注射液的方法。方法:用Diamonsil C_(18)柱,以甲醇—水(10:90)为流动相,流速0.6ml·min~(-1),检测波长230nm。结果:吡拉西坦线性范围0.17～0.78mg·ml~(-1),r=0.9995。平均回收率为100.0％,RSD为0.24％(n=6)。结论:方法简便、准确、重现性好,可作为该制剂的含量测定方法。     

复方丹参注射液对动物学习记忆能力的影响

目的:观察并比较复方丹参注射液和吡拉西坦(脑复康)对大鼠和小鼠学习记忆能力的影响。方法:以东莨菪碱和乙醇分别造成动物学习记忆获得障碍和记忆再现障碍,采用迷津法和跳台法进行测试,结果:复方丹参注射液和脑复康对东莨菪碱和乙醇所致的学习记忆障碍均有改善作用(与模型组比较,复方丹参组均为P<0.05,脑复康组均为0.05相似文献   

Do piracetam-like compounds act centrally via peripheral mechanisms?

The pharmacological mechanism of action of the piracetam-like nootropics is still obscure. Their unique feature is that they exert distinct effects on memory, but show hardly any biochemical activity and are practically devoid of toxic effects. Our results indicate that the memory-enhancing action of these substances is dependent on the presence of the adrenals, suggesting that their central effects might be mediated by peripheral mechanisms.     

司坦唑醇与吡拉西坦联用对D-半乳糖致大鼠股骨损伤的影响

目的:研究司坦唑醇与吡拉西坦联用对D-半乳糖致大鼠股骨损伤的影响。方法:将大鼠随机分为正常对照组、模型组和联用组,每组10只,后2组皮下注射D-半乳糖(100mg·kg-1·d-1)建立骨质疏松症模型,建模后联用组灌胃给予司坦唑醇0.54mg·kg-1·d-1、吡拉西坦432mg·kg-1·d-1,连续给药14周。检测各组大鼠左侧股骨长和宽,干湿重/体重比和骨羟脯氨酸(Hyp)、骨钙、骨磷含量;右侧股骨最大载荷、弹性载荷、断裂载荷、刚性系数和弯曲能量。结果:与正常对照组比较,模型组大鼠股骨干湿重/体重比和骨钙、弹性载荷均明显降低(P<0.05),其余指标均无明显变化(P>0.05);与模型组比较,联用组股骨干重/体重比、弹性载荷均明显增加(P<0.05),其余指标无明显变化(P>0.05)。结论:司坦唑醇与吡拉西坦联用能有效预防D-半乳糖致大鼠股骨重量降低,增强骨强度。     

依达拉奉对血管性痴呆患者认知功能的影响

目的 观察依达拉奉对血管性痴呆患者认知功能的影响.方法 70例轻中度血管性痴呆患者随机分为观察组(采用依达拉奉治疗)和对照组(采用吡拉西坦治疗)各35例,疗程为2周,采用简易精神状态检查(MMSE)、画钟试验(CDT)和蒙特利尔认知评估量表(MoCA)评估两组认知功能.结果 观察组治疗后MMSE、CDT、MoCA评分与治疗前差异均有统计学意义(t=4.21、1.45、12.37,均P＜0.05),对照组治疗后与治疗前差异均无统计学意义(均P＞0.05).结论 依达拉奉通过清除自由基,抗氧化损伤,能够改善血管性痴呆患者的认知功能.     

吡拉西坦注射液治疗高颅内压66例

目的探讨吡拉西坦注射液降低颅内压的临床疗效。方法将黔江中心医院2010年5月至2011年5月收治的颅脑损伤、脑出血非手术治疗患者132例,随机分为研究组和对照组,每组66例。研究组静脉快速滴注20%吡拉西坦注射液,对照组静脉快速滴注20%甘露醇注射液。所有患者均采用持续颅内压监护或定时腰椎穿刺测颅内压。结果研究组显效8例,有效28例,进步28例,无效2例;对照组显效6例,有效26例,进步32例,无效2例。两组总有效率均为96.97%,无显著性差异(P>0.05)。用药期间研究组未观察到与所用药品有关的不良反应。结论吡拉西坦注射液脱水、降颅内压效果明显,安全可靠,无明显不良反应。     

三种脑神经细胞活化药治疗脑梗死的疗效比较

目的;观察脑神经细胞活化药(脑活化药)吡拉西坦(Pira)、氨基酸/低分子肽(NGP)、三磷酸胞苷二钠(CTP)对急性脑梗死治疗的临床疗效.方法;随机分治疗组150例和对照组50例.治疗组分为Ⅰ、Ⅱ、Ⅲ组,分别用(Pira)8.0 g&#8226;d 1、NGP 40 mg&#8226;d 1、CTP 80 mg&#8226;d 1治疗1个疗程(15 d),起病1周内开始用药.于用药当天和用药结束时,对患者进行神经功能缺损评分及临床疗效评定.对照组选择没有运用脑活化药的病例,于用药第7,15天进行临床疗效评定.结果;脑活化药治疗组治疗前后神经功能缺损评分显著性降低(P＜0.05),有效率和总进步率都显著高于对照组(P＜0.05).结论;Pira、NGP、CTP单独运用对急性脑梗死治疗均有一定的临床疗效.     

吡拉西坦改善慢性精神分裂症患者认知功能的临床研究

目的 探讨吡拉西坦改善慢性精神分裂症患者认知功能的效果。方法 对68例慢性精神分裂症患者随机分为试验组和治疗组。治疗前进行阳性和阴性症状量表(PANSS)、简明精神状态量表(MMSE)、中国修订韦氏成人智力量表、韦氏记忆量表(WMS)及威斯康星卡片分类测验等评定,然后经利培酮(2.7±0.8)mg/d治疗8周。研究组与利培酮治疗同步使用吡拉西坦1200mg/d治疗,治疗组仅用利培酮治疗。治疗后第8周末再次进行上述评定,将结果与正常人组成的对照组进行比较。结果 治疗前研究组和治疗组的MMSE、WMS及WAIS-RC均低于对照组,差异有非常显著性(P<0.05),提示患者组的认知功能呈广泛性损害;研究组治疗后认知功能评定MMSE、MCST、WMS、WAIS-RC分数与治疗前比较有显著性差异(P<0.05);而治疗组治疗后认知功能测定MCST、WMS、WAIS-RC分数与治疗前比较无差异性(P>0.05)。结论 吡拉西坦对神经细胞有激活、保护和修复作用,能有效改善患者的认知功能,疗效确切。     

Piracetam-induced improvement of mental performance

A double-blind, intra-individual cross-over comparison of the mental performance of 18 aging, non-deteriorated individuals during two 4-week periods of piracetam (1-acetamide-2-pyrrolidone) and placebo administration was performed using conventional and computerized perceptual-motor tasks. In a majority of these tasks the subjects did significantly better when on piracetam than on placebo, a finding consistent with ratings completed by two independent observers. The findings indicate new avenues for the treatment of individuals with reduced mental performance possibly related to disturbed alertness — a neglected group of psychiatric conditions.